Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of AMG 706 in Locally Advanced or Metastatic Thyroid Cancer
2005-001618-42Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of motesanib in thyroid cancer, Medullary Thyroid Cancer (MTC) and well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Amgen. Primary endpoint: Objective response rate. Started Jun 2005; status: completed.
02
Drugs
motesanib
03
Conditions
thyroid cancerMedullary Thyroid Cancer (MTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2005-001618-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001618-42.